Skip to main content

Bydureon BCise FDA Approval History

FDA Approved: Yes (First approved October 20, 2017)
Brand name: Bydureon BCise
Generic name: exenatide
Dosage form: Extended-Release Injectable Suspension
Company: AstraZeneca
Treatment for: Diabetes, Type 2

Bydureon BCise (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients with type 2 diabetes.

Development timeline for Bydureon BCise

DateArticle
Jul 23, 2021Approval Bydureon BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
Apr  3, 2018Approval FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
Oct 23, 2017Approval FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes
Mar  3, 2014Approval FDA Approves Bydureon Pen for Once-Weekly Treatment of Adults with Type 2 Diabetes
Jan 27, 2012Approval FDA Approves Bydureon - The First and Only Once-Weekly Treatment for Type 2 Diabetes
Aug 10, 2011Bydureon FDA Action Date Set for January 28, 2012
Jul 28, 2011Bydureon Reply Submitted to FDA
Oct 20, 2010Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for Bydureon
May  6, 2010Bydureon FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Apr 23, 2010Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for Bydureon

See also

Bydureon BCise (exenatide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer